DERMATOLOGICAL SIDE EFFECTS OF CURRENT AND UPCOMING TARGETED THERAPIES IN ONCOLOGY

REFERENCES

• Lacouture M. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803–812.
   PubMed Web of Science ®Google Scholar
• Tan EH, Chan A. Evidence-based treatment options for management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Phar-macother 2009:43: 1658–1666.
   PubMed Web of Science ®Google Scholar
• Dick SE, Crawford GH. Managing cutaneous side effects of epidermal growth receptor (HER1/EGFR) inhibitors. Community Oncology 2005; 2:492–496.
   Google Scholar
• Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16:1425–1433.
   PubMed Web of Science ®Google Scholar
• Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol 2008; 58: 454–470.
   Google Scholar
• Pérez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/ EGFR inhibitor rash management forum. The Oncologist 2005; 10: 345–356.
   PubMed Web of Science ®Google Scholar
• Gerber P. Buhren B, Ude S, Homey B. Therapie mit Inhibitoren des epidermalen Wachstumsfaktorrezeptors. Hautarzt 2010; 61: 654–661.
   Google Scholar
• Segaert S. Huidtoxiciteit van epidermale groeifactorreceptor (EGFR)-inhibitoren. Skin 2010; 13(6): 168–170.
   Google Scholar
• Micantonio T, Fargnoli MC, Ricevuto E, et al. Efficacy of treatment with tetracy-dines to prevent acneiform eruption secondary to cetuximab therapy. Arch Dermatol 2005; 141:1173–1174.
   Web of Science ®Google Scholar
• Jatoi A, Rowland K, Sloan J, et al. Tetracycline to prevent epidermal growth fac-tor receptor -induced skin rashes. Results of a placebo-controlled trial of the North Central Cancer Treatment Group. Cancer 2008; 113: 847–853.
   PubMed Web of Science ®Google Scholar
• McCubrey J, Steelman L, Abrams S, et al. Emerging MEK inhibitors. Expert Opin. Emerging Drugs 2010; 15(2): 203–223.
   PubMed Web of Science ®Google Scholar
• Adjei A, Cohen R, Franklin W, et al. Phase I pharmacokinetic and pharmacody-namic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26: 2139–2146.
   PubMed Web of Science ®Google Scholar
• Desar I, Bovenschen H, Timmer-Bonte A, et al. Case studies showing clinical sings ans management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours. Acta Oncol 2010; 49: 110–113.
   Google Scholar
• Balagula Y, Huston K, Busam K, et al. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs Epub 27 October 2010.
   Google Scholar
• LoRusso P. Krishnamurthi S, Rinehart J, et al. Phase I pharmacokinetic and phar-macodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010; 16(6): 1924–1937.
   PubMed Web of Science ®Google Scholar
• Haura E, Rican A, Larson T, et al. A phase II study of PD-0325901, an oraIMEK inhibitor, in previously treated patients with advanced non-small cell lung can-cer. Clin Cancer Res 2010; 16(8): 2450–2457.
   PubMed Web of Science ®Google Scholar
• Rinehart J, Adjei A, LoRusso P. et al. Multicenter phase ll study of the oral MEK inhibitor CI-1040 in patients with advanced non-small-cell lung, breast, colon and pancreatic cancer. J Clin Oncol 2004; 22: 4456–4462.
   PubMed Web of Science ®Google Scholar
• LoRusso P. Adjei A, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23: 5281–5293.
   Web of Science ®Google Scholar
• Schad K, Bauman Conzett K, Zipser M, et al. Mitogen-activated protein/extracel-lular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disor-ders. Clin Cancer Res 2010; 16(3): 1058–1064.
   PubMed Web of Science ®Google Scholar
• Flaherty K, Puzanov I, Kim K, et al. Inhibiton of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809–819.
   PubMed Web of Science ®Google Scholar
• Blay J-Y. Updating progress in sarcoma therapy with mTOR inhibitors. Ann Oncol 2010 Jun 29 (Epub).
   Web of Science ®Google Scholar
• Mahe E, Morelon E, Lechaton S. et al. Cutaneous adverse events in renal trans-plant recipients receiving sirolimus-based therapy. Transplantation 2005; 79(4): 476–482.
   PubMed Web of Science ®Google Scholar
• Campistol J, de Fijter J, Flechner S. Langone A, Morelon E, Stockfleth E. mTor inhibitor-associated dermatologic and mucosa! problems. Clin Transplant 2010; 24: 149–156.
   PubMed Web of Science ®Google Scholar
• Mahe E, Morelon E, Lechaton S, Kreis H, de Prost Y, Bodemer C. Angioedema in renal transplant recipients on sirolimus. Dermatology 2007; 214: 205–209.
   PubMed Web of Science ®Google Scholar
• Desai N, Heenan S. Mortimer P. Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism. Br J Dermatol 2009; 160: 1322–1326.
   PubMed Web of Science ®Google Scholar
• Ghandi M, Kuzel T, Lacouture M. Eosinophilic rash secondary to temsirolimus. Clin Genitourin Cancer 2009; 7(2): E34–E36.
   Web of Science ®Google Scholar
• Monaco A. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009; 87(2): 157–163.
   Web of Science ®Google Scholar
• Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 2010; 36:416–424.
   PubMed Web of Science ®Google Scholar
• Wozel G, Sticherling M, Schön M. Cutaneous side effects of inhibition of VEGF signal transduction. J Dtsch Dermatol Ges 2010; 8: 243–249.
   Web of Science ®Google Scholar
• Amselem L, Diaz-Llopis M, Garcia-Delpech S, Montero J, Palomares P. Cervera E. Papulopustular eruption after intravitreal bevacizumab (Avastire). Acta Oph-thalmol 2009; 87(1): 110–111.
   Web of Science ®Google Scholar
• Ladas I, Moschos M, Papakostas T, Kotsolis A, Georgalas I, Apostolopoulos M. Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularisation. Clin Ophthalmol 2009; 3: 129–131.
   Google Scholar
• Motl S. Bevacizumab in combination with chemotherapy for colorectal and other cancers. Am J Health Syst Pharm 2005; 62: 1241.
   Web of Science ®Google Scholar
• Vano-Galvan S, Moreno C, Medina J, Perez-Garcia B, Garcia-Lopez J, Jaen P. Per-forating dermatitis in a patient receiving bevacizumab. J Eur Acad Dermatol Venereol 2009; 23: 972–974.
   Google Scholar
• Ruiz V. Garcia-Muret M, Alomar A. Hand eruption after intravenous administra-tion of bevacizumab. J Eur Acad Dermatol Venereol 2011; 25: 238–239.
   Web of Science ®Google Scholar
• Stone R, Soof A, Coleman R. Collateral damage: toxic effects of targeted antian-giogenic therapies in ovarian cancer. Lancet Oncol 2010; 11: 465–475.
   PubMed Web of Science ®Google Scholar
• Rosman I, Anadkat M. Tufted hair folliculitis in a woman treated with trastu-zumab. Target Oncol 2010; 5(4): 295–296.
   Web of Science ®Google Scholar
• Abe H, Umeda T, Kawai Y, et al. Adjuvant trastuzumab can be infused safely over 30 minutes. Gan To Kagaku Ryoho 2010; 37(10): 1887–1891.
   Google Scholar
• Hodi F, O'Day S, McDermott D, et al. improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med 2010; 363(8): 711–23.
   PubMed Web of Science ®Google Scholar
• Kähler K, Hauschild A. Treatment and side effects management of CTLA-4 anti-body therapy in metastatic melanoma. J Dtsch Dermatol Ges 2010 Nov 17 [Epub ahead of print].
   Google Scholar